Pamela Cruz. Pensula 360 Press.
US pharmaceutical company Pfizer and German firm BioNTech reported that studies of their COVID-19 vaccine have shown superior efficacy to 90% in participants who had no previous evidence of infection with the virus.
Thus, during the first analyses of phase three of the study of this vaccine, a level of protection of 90% against the virus was achieved, just 28 days after the first dose and seven days after the second application.
However, in a statement, both companies warned that the final efficacy could vary as the study progresses.
And so far, they have been released, no incident has been reported.